U.S. pharma large copyright scrapped two experimental weight loss products previous calendar year—a at the time-every day pill, lotiglipron, resulting from elevated liver enzymes and also a twice-daily capsule, danuglipron, as a consequence of potent Unintended effects—but CEO Albert Bourla has reported the company is decided to “Perform and